- Home
- SPH vs SPRY Comparison
SPH vs SPRY Comparison
Compare SPH & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- SPRY
- Stock Information
- Founded
- SPH 1945
- SPRY 2015
- Country
- SPH United States
- SPRY United States
- Employees
- SPH N/A
- SPRY N/A
- Industry
- SPH Other Specialty Stores
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- SPRY Health Care
- Exchange
- SPH Nasdaq
- SPRY Nasdaq
- Market Cap
- SPH 1.2B
- SPRY 1.4B
- IPO Year
- SPH 1996
- SPRY N/A
- Fundamental
- Price
- SPH $18.38
- SPRY $14.49
- Analyst Decision
- SPH Buy
- SPRY Strong Buy
- Analyst Count
- SPH 2
- SPRY 4
- Target Price
- SPH $21.00
- SPRY $28.75
- AVG Volume (30 Days)
- SPH 134.6K
- SPRY 1.5M
- Earning Date
- SPH 05-08-2025
- SPRY 08-05-2025
- Dividend Yield
- SPH 7.10%
- SPRY N/A
- EPS Growth
- SPH N/A
- SPRY N/A
- EPS
- SPH 1.46
- SPRY N/A
- Revenue
- SPH $1,424,243,000.00
- SPRY $97,122,000.00
- Revenue This Year
- SPH $10.99
- SPRY N/A
- Revenue Next Year
- SPH N/A
- SPRY $140.40
- P/E Ratio
- SPH $12.55
- SPRY N/A
- Revenue Growth
- SPH 4.02
- SPRY 971120.00
- 52 Week Low
- SPH $15.20
- SPRY $7.55
- 52 Week High
- SPH $22.24
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- SPH 36.50
- SPRY 53.45
- Support Level
- SPH $18.13
- SPRY $13.28
- Resistance Level
- SPH $19.25
- SPRY $14.87
- Average True Range (ATR)
- SPH 0.43
- SPRY 0.79
- MACD
- SPH -0.04
- SPRY -0.06
- Stochastic Oscillator
- SPH 18.25
- SPRY 54.50
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.